Nav: Home

Pairing cancer genomics with cognitive computing highlights potential therapeutic options

November 20, 2017

CHAPEL HILL - A University of North Carolina Lineberger Comprehensive Cancer Center-led study has demonstrated the ability of cognitive computing to scour large volumes of data from scientific studies and databases to identify potentially relevant clinical trials or therapeutic options for cancer patients based on the genetics of their tumors.

The researchers said their findings, published in the journal The Oncologist, suggest that cognitive computing applications could help physicians to stay abreast of an ever-expanding body of scientific literature as well as highlight potential therapeutic options, specifically as it relates to cancer genetics.

"Our findings, while preliminary, demonstrate that cognitive computing might have a role in identifying more therapeutic options for cancer patients," said UNC Lineberger's William Kim, MD, the study's corresponding author and an associate professor of medicine and genetics in the UNC School of Medicine. "I can tell you that as a practicing oncologist, it's very reassuring for patients to know that we're able to explore all possible options for them in a very systematic manner."

The study's first authors were Nirali Patel, MD, formerly of UNC Lineberger, and Vanessa Michelini of IBM Watson Health, Boca Raton, Florida. IBM Corp. provided in-kind access to the Watson technology for the study, as well as technical expertise.

The researchers used IBM Watson for Genomics to assess whether cognitive computing was more effective than a panel of cancer experts in identifying therapeutic options for tumors with specific genetic abnormalities. They compared Watson's ability to identify possible therapeutic options tied to potentially clinically significant genetic mutations with the findings of UNC Lineberger's molecular tumor board.

In a retrospective analysis of 1,018 cancer cases, the molecular tumor board identified actionable genetic alterations in 703 cases, which Watson also confirmed. In addition, Watson for Genomics identified additional potential therapeutic options in 323 patients, or one third of the cases reviewed that the molecular tumor board hadn't identified. Of these, 96 were not previously identified as having an actionable mutation.

"To be clear, the additional 323 cases of Watson-identified actionable alterations consisted of only eight genes that had not been considered actionable by the molecular tumor board," Kim said. In most of those cases, Watson identified a new clinical trial. One of those trials had opened within a week of Watson's analysis.

The study drew on data from UNCseq, a UNC Lineberger clinical trial that used next-generation sequencing to analyze the genomics of a participant's tumor with the goal of matching tumor abnormalities with a targeted therapeutic. Next-generation sequencing is "fundamental" to the promise of precision medicine, the researchers reported, but sequencing can uncover many different alterations in hundreds of genes, and the "majority of such events have no known relevance to the treatment of patients with cancers."

"The major finding is that cognitive computing augmented the molecular tumor board process for the interpretation and collection of information regarding a patient's genomic profile," Kim said. "The study was not designed to analyze whether or not this helps patients in regard to outcome as defined by prolonged survival or treatment response."

The program did identify new possible options for some patients. The findings were not relevant to most patients because the majority of the patients did not have active cancer, or had died by the time of the retrospective analysis. But for 47 patients with active disease, and needing additional options, the findings were reported to their treating physicians.

"To my knowledge, this is the first published examination of the utility of cognitive computing in precision cancer care," Kim said. "I'm optimistic that as we get more sequencing data, well-annotated treatment information, as well as therapy response, tools like Watson for Genomics will begin to show their true promise. But, of course, we still need to formally answer these questions."
-end-
The research was supported with grant funding from the University Cancer Research Fund and the National Cancer Institute. Kim has served in an advisory role with IBM. A complete listing of disclosures for all authors is included in the paper.

In addition to Kim, Patel and Michelinni, the paper's other authors were Jeff M. Snell and Joel S. Parker, PhD, UNC Lineberger and UNC Department of Genetics; Michele C. Hayward, Saianand Balu, Alan P. Hoyle, Ashley H. Salazar, and H. Shelton Earp, MD, UNC Lineberger; David A. Eberhard, MD, PhD, UNC Lineberger and UNC Department of Pathology and Laboratory Medicine; Patrick McNeillie, MD, Jia Xu, PhD, and Claudia S. Huettner, PhD, IBM Watson Health, Cambridge, Massachusetts; Takahiko Koyama, PhD, Filippo Utro, PhD, Kahn Rhrissorrakrai, PhD, Raquel Norel, PhD, Erhan Bilal, PhD, Ajay Royyuru, PhD, and Laxmi Parida, PhD, IBM Research, Yorktown Heights, New York; Juneko Grilley-Olson, MD, UNC Lineberger and UNC Department of Medicine; D. Neil Hayes, MD, MPH, formerly UNC Lineberger and UNC Department of Medicine; Norman E. Sharpless, MD, formerly UNC Lineberger, UNC Department of Genetics and Department of Medicine; and Stephen J. Harvey, IBM Watson Health, Herndon, Virginia.

UNC Lineberger Comprehensive Cancer Center

Related Cancer Articles:

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.
Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.
Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.
Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.
Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.
Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.
More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.
New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.
American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.
Oncotarget: Cancer pioneer employs physics to approach cancer in last research article
In the cover article of Tuesday's issue of Oncotarget, James Frost, MD, PhD, Kenneth Pienta, MD, and the late Donald Coffey, Ph.D., use a theory of physical and biophysical symmetry to derive a new conceptualization of cancer.
More Cancer News and Cancer Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Listen Again: The Power Of Spaces
How do spaces shape the human experience? In what ways do our rooms, homes, and buildings give us meaning and purpose? This hour, TED speakers explore the power of the spaces we make and inhabit. Guests include architect Michael Murphy, musician David Byrne, artist Es Devlin, and architect Siamak Hariri.
Now Playing: Science for the People

#576 Science Communication in Creative Places
When you think of science communication, you might think of TED talks or museum talks or video talks, or... people giving lectures. It's a lot of people talking. But there's more to sci comm than that. This week host Bethany Brookshire talks to three people who have looked at science communication in places you might not expect it. We'll speak with Mauna Dasari, a graduate student at Notre Dame, about making mammals into a March Madness match. We'll talk with Sarah Garner, director of the Pathologists Assistant Program at Tulane University School of Medicine, who takes pathology instruction out of...
Now Playing: Radiolab

What If?
There's plenty of speculation about what Donald Trump might do in the wake of the election. Would he dispute the results if he loses? Would he simply refuse to leave office, or even try to use the military to maintain control? Last summer, Rosa Brooks got together a team of experts and political operatives from both sides of the aisle to ask a slightly different question. Rather than arguing about whether he'd do those things, they dug into what exactly would happen if he did. Part war game part choose your own adventure, Rosa's Transition Integrity Project doesn't give us any predictions, and it isn't a referendum on Trump. Instead, it's a deeply illuminating stress test on our laws, our institutions, and on the commitment to democracy written into the constitution. This episode was reported by Bethel Habte, with help from Tracie Hunte, and produced by Bethel Habte. Jeremy Bloom provided original music. Support Radiolab by becoming a member today at Radiolab.org/donate.     You can read The Transition Integrity Project's report here.